bioAffinity Technologies, Inc. (BIAF) Form 424B5 — Oct 9, 2026
bioAffinity Technologies priced a ~$4.0 million direct offering of 116,545 shares at $6.122 per share, plus pre-funded warrants on up to 536,836 shares and unregistered warrants on 980,072 shares, with WallachBeth acting as exclusive placement agent for a 7.5% fee. After fees, the company nets roughly $4 million, lifting pro forma cash from about $5.9 million to $9.5 million — critical runway for a company whose auditors have flagged substantial doubt about going concern. The offering price sits just below the October 7, 2025 close of $6.16.
Key figures
- Cash Position
- 9480485
- Gross Proceeds
- 3996241
- Offering Price
- 6.122
- Shares Offered
- 116545
- Shares Outstanding
- 1283170
- Dilution per share
- 1.32
- Pre funded warrants
- 536,836 warrants at $0.007 exercise price
- Reverse split ratio
- 1:15 (effective Aug 24, 2026)
- Placement agent fees
- 299718
- Q3 2026 cypath unit growth
- 100% YoY
- Unregistered warrant shares
- 980072
- Placement agent warrant shares
- 19602
- Aggregate market value non affiliates
- 17707794
AI analysis
Red flags7 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.